Kornimate/medical-research-clean huggingface dataset:
strength expansion

Conditions: Esophageal Cancer; Gastroesophageal Junction Cancer

Summary: patients seen in the egmdc (esophageal and gastric multidisciplinary clinic) for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at uccc metro will be offered enrollment into the study. patients will complete the self-assessments outlined below on provided tablet computers during uccc visits. if unable to complete assessments in person they will be e-mailed via redcap survey to the patient to complete individually.

patients with esophageal (ec) and gastroesophageal junction (gejc) cancers who are seen in the esophageal and gastric multidisciplinary clinic (egmdc) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at uccc metro will be offered enrollment into the study. patients will complete the patient reported assessments focused on qol and physical activity on provided tablet computers during uccc visits at specified time points. if unable to complete assessments in person they will be e-mailed to the patient via redcap to complete. additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.

Eligibility criteria:
inclusion criteria: 1. provision to sign and date the consent form 2. age ≥ 18 years 3. receiving treatment according to the strength pathway 4. diagnosed with esophageal(ec)/gastroesophageal junction cancer(gejc) stage ib-iiib 5. planning to receive neoadjuvant treatment followed by surgery at university of colorado cancer center (uccc) metro 6. ability to complete surveys online via an emailed redcap survey link if unable to complete in person exclusion criteria: 1. inability to read english and complete questionnaires independently 2. per the investigator, unable to comply with study criteria or assessments 3. inability to receive and complete redcap survey online
glucose variability in type 1 diabetes and its effect on factors that influence new vessel formation

Conditions: Type 1 Diabetes

Summary: the aim of the study is to see how glycaemic control and glycaemic variability affect levels of hif, vegf, erythropoietin and cortisol in paediatric type 1 diabetics on insulin pump therapy.

the study will have two parts. the first phase will look at all current paediatric type 1 diabetics in tayside on continuous subcutaneous insulin pump therapy and measure their levels of hypoxia-inducible factor (hif), vascular endothelial growth factor (vegf), erythropoietin and cortisol. this will help answer the question; does glucose control (as expressed by hba1c ) effect levels of hif, vegf, erythropoietin and cortisol? to our knowledge this will be the first human study comparing how hif, vegf, erythropoietin and cortisol are affected by glucose control the second phase of the trial will chose 10 patients on insulin pump therapy and using a continuous glucose monitor (cgm), monitor their glucose variability over a period of 6 weeks. after this period their levels of hif, vegf, erythropoietin and cortisol will again be measured. this will help answer the question of whether there is a relationship between glucose variability and levels of hif, vegf, erythropoietin and cortisol. as we know that these factors are stimulated by episodes of hypo and hyperglycaemia, it is hypothesised that these factors will be lower in participants that demonstrate reduced glucose variability. it will be the first study to give detailed information on the relationship between hif, vegf, erythropoietin and cortisol and glucose variability. by using telemedicine sessions during weeks 1, 3 and 5 of the participants wearing cgm we will aim to improve the participant's glucose variability. this will help give further information about glucose variability and the above factors as well as giving further evidence for the use of telemedicine and cgm to improve glycaemic control in adolescent diabetics.

Eligibility criteria:
inclusion criteria: phase 1 inclusion: * patients with type 1 diabetes * on insulin pump therapy. * aged 5 years to 18 years. phase 2 inclusion: * patents with type 1 diabetes * diabetes diagnosis for 1 year * on insulin pump therapy for minimum of six months * access to a computer with internet access and telephone * agree to wear cgm for 6 weeks * aged 12 years to 18 years exclusion criteria: * patients not on pump therapy * patient less than 5 years and greater than 18 years * phase 2 patients been on pump therapy for less than 6 months * phase 2 patients without access to internet and telephone. * phase 2 patients less than 12 years and greater than 18 years * patients who do not have a good understanding of english

Keywords: glucose variability continuous glucose monitoring hypoxia-inducible factor (hif) vascular endothelial growth factor (vegf) erythropoietin cortisol
comparison of low-level laser therapy and transcutaneous electrical nerve stimulation for myofascial pain in temporomandibular disorders

Conditions: Myofascial Temporomandibular Disorders

Summary: myofascial pain is the most common form of temporomandibular disorder (tmd) encountered in maxillofacial practice. treatment options range from conservative management to open surgical procedures, with physical therapies identified as the safest and most effective. among these, transcutaneous electrical nerve stimulation (tens) is a widely used technique, while low-level laser therapy (lllt) is a recent therapeutic advancement. this study is designed to compare the efficacy of these two therapies, aiming to identify the more effective option.

a randomized clinical trial will be conducted at the oral and maxillofacial surgery department, punjab dental hospital, lahore. sample size of 40 patients will be selected through convenience sampling and divided into two equal groups, based on computergenerated random numbers. a written consent will be obtained from all the participants. group a will receive lllt, while group b will receive tens. the primary variables like pain score and mouth opening will be recorded preoperatively and during followup sessions. the proforma used for data collection will be designed, tailored to the needs of this study based on standard diagnostic criteria for temporomandibular disorders (dc/tmd). both groups will receive their assigned therapies on alternate days for three weeks, with evaluations at 1st, 3rd, and 4th weeks post-treatment. all collected data will be entered into spss version 25 for statistical analysis. independent sample t-test will be used to compare the mean pain score and mouth opening between the two groups. repeated measures anova will be applied to compare the primary variables in both groups on all follow-ups. p-value ≤0.05 will be considered as significant. this study aims to offer tailored insights and practical recommendations, potentially improving patient care by providing safer and non-invasive alternatives to more invasive procedures thus enhancing overall treatment strategies. it is assumed that expected results shall be in favor of the lllt group. possible limitations may include failure of patients to come for multiple sessions.

Eligibility criteria:
inclusion criteria: 1. diagnosed cases of myofascial pain in tmd patients, which fall under diagnostic criteria (dc/tmd). 2. myofascial pain that persists for more than 3 months. 3. involvement of trigger points in the masseter and temporalis muscles. 4. impaired or limited mouth opening (less than 35mm). exclusion criteria: 1. congenital abnormality or neoplastic condition around tmj. 2. recent history of trauma affecting head and neck region. 3. patients with known dermatological disorders (eczema, psoriasis). 4. patients with pacemakers and cardiovascular diseases. 5. epileptic patients. 6. patients allergic to adhesive tapes or electrodes of tens

Keywords: randomized clinical trial temporomandibular disorder myofascial pain low-level laser therapy transcutaneous electrical nerve stimulation jaw pain treatment mouth opening improvement
positron emission tomography (pet) imaging of participants with confirmed prostate cancer using 64cu-sar-bispsma (propeller)

Conditions: Prostatic Neoplasms

Summary: the aim of this study is to determine the safety and tolerability of 64cu-sarbispsma in participants with untreated, confirmed prostate cancer.

this is a multi-centre, blinded review, dose ranging, non-randomized study of 64cu-sar-bispsma administered to participants with confirmed prostate cancer. 30 eligible participants will be allocated (1:1:3) to 1 of 3 dosing cohorts to be administered with 64cu-sar-bispsma 100 mbq, 150 mbq or 200 mbq. pet/ct scan images will be sent to blinded central readers to assess the capacity of 64cu-sar-bispsma to detect primary prostate cancer, to assess image quality of the various dose cohorts, and to assess the pet/ct scan features of 64cu-sar-bispsma in comparison standard of care.

Eligibility criteria:
inclusion criteria: * signed informed consent; * ≥18 years of age; * life expectancy \>3 months; * confirmation of prostate cancer by histopathology and planned radical prostatectomy; * have ≥1 of the following intermediate- to high-risk features: 1. psa level greater than or equal to 10.0 ng/ml within 12 weeks prior to enrolment; 2. international society of urological pathology (isup) grade group 3 (i.e. gleason score of 7 (4+3) or above; 3. clinical stage greater than or equal to t2b; * participants must have adequate renal function; * sexually active participants who have female partners of childbearing potential: partner and/or participant must agree to use an acceptable form of contraception. further participants must refrain from donating sperm; * a 68ga-psma-11 pet/ct scan performed within 5 weeks, but not closer than 6 hours prior to the administration of 64cu-sar-bispsma. exclusion criteria: * prior prostatectomy or any other treatment for prostate cancer, including androgen deprivation therapy and radiation therapy; * previous treatment with psma-targeted therapy within 3 months prior to enrolment, and administration of other investigational agents within 4 weeks prior to entering the study (except 68ga-psma-11); * known hypersensitivity to the components of 64cu-sar-bispsma; * diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. however, participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer, superficial bladder cancer; * any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study; * patients unwilling or unable to comply with protocol or with a history of noncompliance or inability to grant informed consent.
morphine in acute abdominal pain

Conditions: Abdominal Pain

Summary: the investigators primary outcome measure was the clinically important change in diagnostic accuracy and physical examination in the morphine vs. placebo group. after follow up information was obtained and patients data were recorded on the spss data chart, two blinded coauthors (general surgeon and emergency physician) determined the clinically important diagnostic accuracy and change in physical examination. they firstly defined clinically important diagnostic errors, as any disagreement between the preliminary and final diagnosis that might be expected to have adverse effect on the patient's general status. if coauthors decided an instance of diagnostic error as clinically important, this was coded "diagnostic discordance" for statistical analysis. while the preliminary diagnosis was determined as accurate or not different from the final diagnosis, this was coded "diagnostic accuracy" for statistical analysis. secondary outcome measures included the need for rescue drugs at 30 minutes, the presence of at least one adverse event, demographic features and final diagnosis of the patients.


Eligibility criteria:
inclusion criteria: * elderly (65 years or older) patients with non-traumatic uap of less than 48 hours' duration were included in the study. participants were required to have a uap and report either "mild" or greater pain intensity on a four-point verbal rating scale (vrs) or at least 20 mm on a 100 mm visual analogue scale (vas). exclusion criteria: * exclusion criteria included known allergy or contraindication to morphine, or any opioid analgesic * hemodynamic instability (systolic blood pressure less than 100 mm-hg) * use of any analgesic within 6 hours before ed presentation * patients refused to participate to the study * incooperated to the vas * isolated flank pain or previous study enrollment * patients with known renal, pulmonary, cardiac or hepatic failure were also excluded.

Keywords: to evaluate the anal. efficacy of iv morph. vs. place. for elderly presenting to the ed with uap and determine if it has an impact on diag. accu. and phy. exam
radiotherapy for nsclc to a individualized mld

Conditions: Non-small Cell Lung Cancer

Summary: our group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased tcp with the same ntcp. in a subsequent phase i trial, the investigators showed the safety of this approach. here, the investigators want to investigate its efficacy in a prospective study in patients with stage i-iii nsclc, who are selected for radical radiotherapy

eligible patients (see below) will receive radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to the following mld (mean lung dose): * mld=19 gy when fev1 and dlco \> 50% of the predicted value * mld=15 gy when fev1 and/or dlco 40-49% of the predicted value * mld=10 gy when fev1 and/or dlco \<40% of the predicted value other dose-constrains: spinal cord max: 54 gy, brachial plexus (dmax):66 gy minimum tumor dose:79.2 gy. radiotherapy will be delivered in twice-daily fractions of 1.8 gy with 8 to 10 h as interfraction-interval, 5 days per week. the radiation doses will be specified according to icru 50. lung density corrections will be applied, as well as all standard qa procedures. technical requirements are the same as in standard practice at maastro clinic.

Eligibility criteria:
inclusion criteria: * histological or cytological proven nsclc * uicc stage i-iii * performance status 0-2 * fev 1 and dlco at least 30% of the age-predicted value exclusion criteria: * not nsclc or mixed nsclc and other histologies (e.g. small cell carcinoma) * uicc stage iv * performance status 3 or more * fev 1 and dlco \< 30% of the age-predicted value

Keywords: radiotherapy nsclc stage iii non-small cell lung cancer
effects of preoperative 3d printing of distal intra-articular radius fractures on quality of fracture reduction

Conditions: Distal Radius Fracture; 3D Printing

Summary: the investigators aim to evaluate the effect of a preoperative 3d printed model (3pas) of distal intraarticular radius fractures on quality of fracture reduction. surgical procedure is equal in the 3pas and in the conventional group. to evaluate the quality of fracture reduction each patient receives a postoperative cat-scan.


Eligibility criteria:
inclusion criteria: * patient older than 18 years * surgery criteria fulfilled * informed consent * intra-articular fracture of the distal radius (ao 23-b and 23-c) (also including avulsion of the processus styloideus ulnae ao/ota 2u3a1.1) in preoperative cat-scan exclusion criteria: * patient does not want a surgical treatment * patient does not want to participate * positive history for surgery due to injury of the hurt wrist beforehand * positive history for surgery due to injury of the opposite wrist beforehand * additional injuries to the hand and forearm (except distal ulna fracture ao 2u3a1.1) * pregnancy * vulnerable people * distal ulna fracture (except ao 2u3a1.1) * extraarticular radius fracture (ao 23-a) * concomitant injuries which interfere with the planned aftercare (intubated for a long time, additional elbow or shoulder fracture)
a study of hetrombopag olamine in chronic idiopathic thrombocytopenic purpura (itp) patients

Conditions: Purpura, Thrombocytopenic, Idiopathic

Summary: the purpose of this study is to obtain information on efficacy, safety and pharmacokinetics (pk)/pharmacodynamics (pd) of hetrombopag over 14 days in chinese patients with chronic itp.


Eligibility criteria:
inclusion criteria: 1. chronical itp patients. 2. the subjects were diagnosed as itp with bone marrow aspiration within 3 months before enrollment or in the screening period. and secondary immune thrombocytopenia (e.g., myelodysplastic syndrome, systemic lupus erythematosus, aplastic anemia) was excluded. 3. patients had a mean platelet count of less than 30,000/µl in the screening period. 4. patients receiving chronic maintenance steroid therapy must have received a stable dose for at least 1 month. 5. patients receiving danazol, mycophenolate mofetil or cyclosporine a must have received a stable dose for at least 12 weeks. 6. normal pt/inr and aptt. exclusion criteria: 1. any prior history of arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), and ≥ two of the following risk factors: hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., factor v leiden, atiii deficiency, etc), or any other family history of arterial or venous thrombosis. 2. pre-existing cardiovascular disease (congestive heart failure, new york heart association \[nyha\] grade iii/iv), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation). 3. malignant disease 4. cancer treatment with cytotoxic chemotherapy and/or radiotherapy. 5. patients with one of the following conditions should be excluded: * treatment with immunoglobulins within 1 week preceding the first dose of study medication. * treatment with splenectomy or rituximab within 12 weeks preceding the first dose of study medication. * treatment with eltrombopag or nplate within 4 weeks preceding the first dose of study medication. * treatment with cyclophosphamide or vinca alkaloids within 4 weeks preceding the first dose of study medication. 6. alt\>2×uln，ast\>2×uln，total bilirubin\>1.5×uln，serum creatinine \>1.2×uln，total albumin \<0.9×lln
cladribine tablets level of response predictors in clinical practice (clodina)

Conditions: Multiple Sclerosis

Summary: this study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (rms) in the long term, in a real-world setting.


Eligibility criteria:
inclusion criteria: * adult participants, male or female patients ≥ 18 years old at index date * participants must voluntarily give written informed consent form (icf). patients must read and fully understand the icf * participants with confirmed diagnosis of rms at index date, diagnosed by the treating physician according to applicable clinical practice guidelines (currently mcdonald 2017 criteria), with high disease activity. * required historical data should be available: number of relapses in the 12 months prior to index date, dmts taken prior to index date, date of ms diagnosis, and data of at least 1 mri prior to index date as specified in the drug summary of product characteristics (smpc) * fulfillment of the indication for treatment with cladribine tablets at index date, per standard of care in accordance with the local smpc * meeting 1 of the following criteria: * prospective participants: having been prescribed with cladribine tablets or having taken at least one dose of cladribine tablets, with enrollment date prior to the second treatment week * retrospective participants: having taken at least one dose of cladribine tablets, with enrollment date during or after the second treatment week but not more than 3 years after the first dose of cladribine tablets exclusion criteria: * contraindications to use of cladribine tablets according to the smpc. * any participant who had the first dose of cladribine tablets more than 3 years prior to enrollment * any participant who is pregnant or plans to breast-feed while taking cladribine tablets, or any patient who or whose partner plans to become pregnant in year 1 or within 6 months after the last dose in year 2, or any participants who is unwilling or unable to use contraception per the smpc * have participated or participating in an interventional study since cladribine tablet initiation, in which participant assessment and/or treatment may be dictated by a protocol * participants who, at the discretion of the investigator, will not be able to provide reliable information for the study

Keywords: multiple sclerosis relapsing multiple sclerosis mavenclad cladribine tablets
interest in combining intraoperative electroencephalogram (eeg) with assessment of frailty to predict postoperative delirium in patients aged >75 years undergoing major non-cardiac surgery

Conditions: Post-operative Delirium

Summary: post-operative delirium (pod) is known to be independently associated with pre-operative frailty, pre-operative cognitive status and per-operative electroencephalogram (eeg). however, no study has focused on the impact of these pre- and peri-operative outcomes on the prediction of post-operative delirium (pod). therefore, this study has been designed to assess the performance of a new score that includes pre-operative frailty, and per-operative electroencephalogram (eeg) in predicting post-operative delirium.


Eligibility criteria:
inclusion criteria: * patients of 75 yo or more undergoing a major non-cardiac surgery exclusion criteria: * patients of less than 75 yo * cardiac surgery * minor surgery * opposition to the study protocol * presence of a delirium prior to the surgery

Keywords: post-operative delirium frailty general anesthesia electroencephalogram electroencephalography older patients clinical frailty scale major non-cardiac surgery